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Abstract
Background: Intracerebral hemorrhage (ICH) is a devastating stroke subtype characterized by a prominent
neuroinflammatory response. Antagonism of pro-inflammatory cytokines by specific antibodies represents a
compelling therapeutic strategy to improve neurological outcome in patients after ICH. To test this hypothesis, the
tumor necrosis factor alpha (TNF-α) antibody CNTO5048 was administered to mice after ICH induction, and
histological and functional endpoints were assessed.
Methods: Using 10 to 12-week-old C57BL/6J male mice, ICH was induced by collagenase injection into the left
basal ganglia. Brain TNF-α concentration, microglia activation/macrophage recruitment, hematoma volume, cerebral
edema, and rotorod latency were assessed in mice treated with the TNF-α antibody, CNTO5048, or vehicle.
Results: After ICH induction, mice treated with CNTO5048 demonstrated reduction in microglial activation/
macrophage recruitment compared to vehicle-treated animals, as assessed by unbiased stereology (P = 0.049). This
reduction in F4/80-positive cells was associated with a reduction in cleaved caspase-3 (P = 0.046) and cerebral
edema (P = 0.026) despite similar hematoma volumes, when compared to mice treated with vehicle control.
Treatment with CNTO5048 after ICH induction was associated with a reduction in functional deficit when compared
to mice treated with vehicle control, as assessed by rotorod latencies (P = 0.024).
Conclusions: Post-injury treatment with the TNF-α antibody CNTO5048 results in less neuroinflammation and
improved functional outcomes in a murine model of ICH.
Keywords: Intracerebral hemorrhage, Microglia, Tumor necrosis factor alpha antagonism, Murine model,
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Introduction
Intracerebral hemorrhage (ICH) is a devastating form
of cerebrovascular disease with higher morbidity and
mortality than ischemic stroke [1] but without any
proven therapy beyond supportive care. Much of the
current clinical research focuses on hematoma reduction
and resolution [2,3], as hemorrhage evolution and volume
are highly correlated with outcome after ICH [4]. However,
the failure of recent large clinical trials [5,6] may be the
result of an inability to fully account for the influence of
secondary injury from the neuroinflammatory response.
Emerging evidence suggests that this inflammatory
response may be tied to outcome and may be modifiable
[7,8]. Future therapeutic strategies may be aimed at
reducing neuroinflammation and inducing or enhancing
recovery mechanisms.
Microglia are the resident immune cells in the central
nervous system (CNS). Microglial activation and macro-
phage infiltration remain the cornerstone of the brain’s
acute response to injury. Microglia are activated through a
variety of different mechanisms and have both destructive
and adaptive roles after ICH [9]. Preclinical evidence
suggests that microglial modulation might improve recovery
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after ICH [10]. Secretion of inflammatory mediators,
such as tumor necrosis factor alpha (TNF-α), is a major
microglial responses to activation, and modulation of this
response may be a promising therapeutic strategy.
TNF-α antagonism has been demonstrated as effective
therapy for a number of chronic inflammatory states [11].
Further, TNF-α modulation may represent a link between
chronic and acute neuroinflammatory states. To test
the hypothesis that TNF-α antagonism is a promising
therapeutic strategy in acute neuroinflammatory states,
a murine analog of the human monoclonal antibody
infliximab, CNTO5048, was tested in a murine model
of ICH.
Methods
This specific research project and all animal procedures
involved were designed to minimize animal discomfort
and numbers, conform to international guidelines on the
use of animals, and were approved by the Duke University
Institutional Animal Care and Use Committee.
Experimental groups
Male C57BL/6J mice (10 to 12 weeks of age; Jackson
Laboratory, Bar Harbor, ME, USA) were used in these
experiments. Prior to ICH induction, mice were randomly
assigned to receive either vehicle (phosphate-buffered
saline (PBS)) or CNTO5048. Vehicle control (PBS) was
used in all experiments.
After randomization, ICH was induced by an operator
blinded to treatment group (BL). To assess the translational
potential of CNTO5048, a separate observer (HW) blinded
to treatment group administered 100 μL of either PBS
or CNTO5048 via tail vein injection at 30 minutes after
injury. These time points for administration and outcome
measurements were chosen based on prior work with
promising therapeutics and neuroinflammatory metrics
[7,10,12-14]. Sham animals were not included in these
experiments as prior work demonstrates that they behave
like uninjured animals [7,10,13,14]. Separate observers
(HND, BL, BRW), blinded to treatment group, assessed
five separate cohorts of mice as follows:
Cohort 1 - Regulation of brain TNF-α. At 4, 24, and 72
hours after ICH induction, the expressions of TNF-α
and cleaved caspase-3 protein were measured in the
ipsilateral hemisphere, using enzyme-linked
immunosorbent assay, bicinchoninic acid assay, and
western blot analysis, respectively (n = 3 mice/group).
The same brain homogenates were used for enzyme-
linked immunosorbent assay and western blot analysis.
Cohort 2 - Unbiased microglial/macrophage
quantification. At 7 days after ICH induction,
immunohistochemical F4/80 staining and cell counting of
bilateral hippocampi was performed (n = 6 mice/group).
Hippocampi were used based on their relationship to
learning and memory, long-term neurological outcome
measures, and our own experience [7,10,12-14].
Cohort 3 - Hematoma volume. At 24 hours after ICH
induction, hematoma volume was measured by
volumetric measurement of hematoxylin and eosin
lesionstaining (n = 7 mice/group).
Cohort 4 - Cerebral edema. At 24 hours after ICH
induction, cerebral edema was assessed by 'wet-to-dry'
brain water content measurement (n = 5 mice/group).
Cohort 5 - Vestibulomotor testing. On Days 0, 1, 3, 5,
and 7 after ICH induction, vestibulomotor function was
assessed by comparing within animal rotorod (RR)
latencies before and after injury (n = 17 to 18 mice/group).
Finally, mortality was compared between treatment
groups in mice surviving 24 hours or longer after
injury.
A timeline of the experiments is provided in Figure 1.
Time points for the assessments were chosen based on
prior experience with this model [7,10,13,14].
Anesthetic technique
Mice were anesthetized with 4.6% isoflurane in 30%
O2/70% N2. After anesthetic induction and loss of response
to tail stimulation, the trachea was intubated, and the
lungs were mechanically ventilated with 1.6% isoflurane in
30% O2/70% N2. Rectal temperature was maintained at
37.0°C ± 0.2°C by an underbody circulating waterbed.
Intracerebral hemorrhage model
The mouse ICH model has been reported previously [13].
After anesthetic induction and intubation, the animal’s
head was secured in a stereotactic frame. The scalp was
incised and a burr hole was created 2.2 mm left lateral to
bregma. A 1.0-μL syringe (Hamilton, Reno, NV, USA)
with a 25-gauge needle was mounted on the stereotactic
frame. The eye of the needle was advanced to a depth of 3
mm from the cortical surface. Type IV-S clostridial colla-
genase (Sigma, St. Louis, MO, USA; 0.075 U in 0.4 μL
0.9% NaCl) was injected over 2 minutes, and the needle
was held motionless for an additional 5 minutes. After
slowly withdrawing the needle, the incision was closed,
and animals were allowed to recover spontaneous ventila-
tion with subsequent extubation. Following recovery in a
warm, non-stimulating environment, mice were allowed
free access to food and water.
Preparation and administration of CNTO5048
CNTO5048, an anti-mouse TNF-α antibody (6.73 mg/mL
in 1X PBS stock) was kindly provided by Janssen Biotech
(Horsham, PA, USA). For all experiments, CNTO5048
was diluted in PBS at 1.75 mg/mL prior to use. A dose of
7 mg/kg was used for all experiments. This dose was
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based on the FDA-approved titration of infliximab from 5
to 10 mg/kg for chronic inflammatory diseases [15].
Quantification of tumor necrosis factor alpha
After anesthetic induction, mice were perfused trans-
cardially with 30 mL PBS. Brains were dissected and
flash frozen in liquid nitrogen, and then stored at -80°C.
Pulverized injured hemispheres were sonicated on ice in
homogenization buffer (20 mM Tris-HCl, pH 8.0, 137
mM NaCl, 2 mM EDTA, 10% glycerol, 1% Triton X-100,
and complete protease inhibitor cocktail tablets; Roche
Diagnostics, Mannheim, Germany) for 20 seconds. Brain
homogenates were incubated on ice for 20 minutes, and
then spun at 10,000 X g at 4°C for 10 minutes. The
supernatant was removed, aliquotted, and stored at -80°C
for protein analysis. Total protein concentrations were
measured using a bicinchoninic acid protein assay reagent
kit (Pierce Biotechnology, Rockford, IL, USA). TNF-α
concentrations in whole-brain homogenates were deter-
mined using an enzyme-linked immunosorbent assay kit
for mouse TNF-α according to the manufacturer’s instruc-
tions (Invitrogen, Camarillo, CA, USA).
Quantification of cleaved caspase-3
From the isolated supernatant isolated, equal amounts of
protein samples were electrophoresed on 4% to 20% SDS-
polyacrylamide gels, and transferred to polyvinylidene
difluoride membranes (Bio-Rad, Hercules, CA, USA). The
membranes were blocked in 5% milk and incubated with
cleaved caspase-3 (Asp175) antibody (1:500; Cell Signaling
Technology, Beverly, MA, USA) overnight at 4°C. After
incubation with secondary horseradish peroxidase-conju-
gated goat anti-rabbit IgG antibody (Pierce Biotechnology),
the blots were detected using Western Dura Extended
Duration Substrate (Pierce Biotechnology). Membranes
were stripped of immunoglobulin and re-probed using
anti-mouse glyceraldehyde-3-phosphate dehydrogenase
(GAPDH, 1:2,000; Cell Signaling).
Immunohistochemistry and stereological analysis
After anesthetic induction, mice were subjected to trans-
cardial perfusion with 30 mL PBS. The brains were rapidly
removed and immersion-fixed in 4% formaldehyde for 24
hours, then transferred into 30% sucrose/1x PBS, and
stored at 4°C for 48 hours. Frozen coronal sections (40 μm)
were collected on a freezing sliding microtome. Floating
brain sections were incubated in 1% hydrogen peroxide,
permeabilized by 0.1% Saponin, and blocked with 10% goat
serum. Sections were incubated overnight with monoclonal
rat anti-mouse F4/80 antibody specific for activated micro-
glia and macrophage (1:20,000; Serotec, Raleigh, NC, USA),
and biotinylated goat anti-rat immunoglobulin G secondary
antibody (1:3000; Vector Laboratories, Inc., Burlingame,
CA, USA) was then applied for 1 hour, followed by avidin-
biotin-peroxidase complex treatment for 1 hour (ABC kit;
Vector Laboratories, Inc., Burlington, CA, USA). Staining
was visualized with diaminobenzidine (DAB kit; Vector
Laboratories, Inc.). After being mounted onto slides, all
sections were counterstained with hematoxylin (Fisher
Scientific, Fair Lawn, NJ, USA). Cells were counted using
a Nikon 218912 light microscope interfaced with the
StereoInvestigator software package (MicroBrightField,
Williston, VT, USA). The number of stained cells per
volume of the hippocampus was estimated by using an
optical fractionator method as previously described [7].
Measurement of hematoma volume
After anesthetic induction, mice were decapitated, and the
brains were removed, flash frozen in 2-methyl butane
(-20°C), and stored at -80°C. Coronal sections 20-μm thick
were serially taken at 400-μm intervals over the rostral-
caudal extent of the lesion. The sections were stained with
hematoxylin and eosin, and lesion area was measured by
digitally sampling stained sections with an image analyzer
(MCID Elite™, Interfocus Imaging, Linton, England).
Hematoma volumes (mm3) were computed as running



















































































































Figure 1 Timeline of experiments. Separate cohorts of animals were used to assess brain TNF-α and cleaved caspase-3 levels, F4/80 cell
positivity, brain water content, hematoma volume, and rotorod latencies.
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between sections (400 μm) over the extent of the lesion,
and expressed as an orthogonal projection.
Measurement of brain water content
After anesthetic induction, mice were decapitated. Brains
were harvested and sectioned mid-sagittally, and each
hemisphere was weighed immediately (‘wet’ weight).
Hemispheres were allowed to dehydrate over 24 hours at
105°C, and were then re-weighed (‘dry’ weight). Cerebral
edema was expressed as calculated water content ((wet
weight - dry weight)/(wet weight) x 100).
Rotorod testing
An automated RR (Ugo Basile, Comerio, Italy) was used
to assess within animal differences in vestibulomotor
function [16]. On the day before ICH induction, mice
underwent two consecutive conditioning trials at a set
rotational speed of 16 revolutions/minute for 60 seconds.
These were followed by three additional trials with 15-
minute intervals and an accelerating rotational speed. The
average time to fall from the rotating cylinder in the final
three trials was recorded as baseline latency. After ICH
induction, three trials with accelerating rotational speed
were conducted on post-injury days 1, 3, 5, and 7. The
average latency to fall from the rod was recorded. A
latency value of 0 seconds indicated inability to grasp the
rotating rod.
Statistical analysis
One-way ANOVA was used to compare TNF-α protein
concentration and cleaved caspase-3 protein band dens-
ities among groups. Student’s t-test was used to compare
hematoma volume, brain water content, and F4/80 cell
counts. Repeated-measures analysis of variance (ANOVA)
with time as the repeated variable was used to compare
RR performance to test group effect as a function of time.
Bonferroni correction was used for repeated measures
technique in ANOVA. Due to differences in pre-injury
latencies, post-injury latencies are reported as percentages
of the baseline. A P value <0.05 was considered statisti-
cally significant. All values were expressed as mean ± SD.
Results
To assess the effects of TNF-α antagonism on microglial
activation, brain TNF-α concentration and downstream
protein expression were measured at 4, 24, and 72 hours
after ICH since TNF-α is an early product of neutrophil
and microglial activation. Brain TNF-α expression was
not affected by CNTO5048 administration (CNTO5048
versus vehicle: 1745 ± 649 versus 1352 ± 21 pg/g at 4
hours after ICH, P = 0.354; 995 ± 161 versus 805 ± 38
pg/g at 24 hours after ICH, P = 0.1179; and 445 ± 58
versus 460 ± 77 pg/g at 72 hours after ICH, P = 0.801).
Notably, brain TNF-α protein concentration peaked at 4
hours after ICH, and then gradually decreased over time,
which is consistent with a previous report [17].
TNF-α activates of the caspase-3 pathway, resulting in
neuronal apoptosis. Moreover, it has been reported that
apoptotic caspases can activate microglia [18]. Therefore,
cleaved caspase-3 (that is, activated caspase-3) was
assessed in ipsilateral hemispheres after neutralization
of TNF-α by CNTO5048 administration. In the same
brain samples used to measure TNF-α concentration, the
CNTO5048-treated group demonstrated a reduction in
cleaved caspase-3 compared to the vehicle-treated group
at 72 hours after ICH (Figure 2).
In this model of ICH, cerebral edema is associated
with the extent of microglial activation and macrophage
recruitment, leading to an increase in vascular permeability
[10,12,13]. To assess the effects of CNTO5048 on micro-
glial activation/macrophage recruitment, F4/80 staining was
performed at 7 days after ICH. The CNTO5048-treated
group demonstrated reduction in F4/80-positive cells in the
ipsilateral hippocampus compared to the vehicle-treated
group (Figure 3).
Functional recovery after ICH is directly related to
hematoma volume and cerebral edema, which is a
consequence of neuroinflammation [8,19,20]. By 24 hours
Figure 2 Cleaved caspase-3 expression after intracerebral
hemorrhage. Representative cleaved caspase-3 western blots (A)
and band density measurements (B) demonstrate reduction at 4, 24,
and 72 hours after intrastriatal collagenase injection in mice given 7
mg/kg CNTO5048 or an equivalent volume of phosphate-buffered
saline (PBS) via tail vein injection at 30 minutes after injury. (ANOVA;
*P = 0.045 compared to PBS at 4 hours, #P = 0.046 compared to PBS
at 72 hours; n = 3/group) CNTO4h, CNTO5048-treated mice at 4
hours after injury; CNTO24h, CNTO5048-treated mice at 24 hours
after injury; CNTO72h, CNTO5048-treated mice at 72 hours after
injury; GAPHD, glyceraldehyde-3-phosphate dehydrogenase; h,
hours; PBS4h, PBS-treated mice at 4 hours after injury; PBS24h,
PBS-treated mice at 24 hours after injury; PBS 72h, PBS-treated mice
at 72 hours after injury.
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after ICH, cerebral edema is maximal, and hemorrhage
evolution has stabilized. Thus, the effects of TNF-α antag-
onism on brain water content and hematoma volume
were assessed between the groups at 24 hours after injury.
The CNTO5048-treated group demonstrated reduced
brain water content compared to the vehicle-treated group
at this time point (Figure 4). At the same time, hematoma
volume was equivalent between the groups (CNTO5048
versus vehicle: 11.49 ± 2.54 versus 9.44 ± 3.04 mm3;
P = 0.304).
Potential clinical efficacy of a novel therapeutic strategy
is difficult to assess without demonstration of functional
recovery after injury in the preclinical setting. To assess
vestibulomotor functional recovery over the acute to
subacute phase of injury, the effects of TNF-α antagonism
on RR latencies were assessed over the first 7 days after
ICH. All animals were able to grasp the rod on all testing
days. However, the CNTO5048-treated group demon-
strated greater return of RR latencies after injury toward
baseline values when compared to the vehicle-treated
group over this time period (Figure 5). Post-injury latencies
are reported as percentages of the baseline latency due
to differences in baseline RR latencies. Finally, the overall
mortality was lower in the CNTO5048-treated group
than in the vehicle-treated group (13.16% versus 23.08%;
P = 0.04).
Discussion
Administration of the TNF-α antibody CNTO5048 de-
creased mortality and improved short-term recovery of
vestibulomotor function while decreasing neuroinflam-
mation in our murine model of ICH. While TNF-α antag-
onism using monoclonal antibodies is a well-established
Figure 3 Macrophage recruitment/microglial activation after
intracerebral hemorrhage. Representative photos of F4/80 positive
cells in ipsilateral hippocampus are shown from CNTO5048-treated
(A) and phosphate-buffered saline-treated (B) mice. As a measure of
microglial activation/macrophage recruitment, F4/80-positive cells
were reduced in the ipsilateral hippocampus 7 days after intrastriatal
collagenase injection in mice given 7 mg/kg CNTO5048 compared
to those treated with an equivalent volume of phosphate-buffered
saline via tail vein injection at 30 minutes after injury. (CNTO5048
versus vehicle: 3,880 ± 949 versus 4,953 ± 691 cells/mm3; t-test;









































Figure 4 Brain water content and hemorrhage volume after
intracerebral hemorrhage. Brain water content (A) was decreased,
while hemorrhage size (B) was unaffected at 24 hours after
intrastriatal collagenase injection in mice given 7 mg/kg CNTO5048
compared to those treated with an equivalent volume of
phosphate-buffered saline via tail vein injection at 30 minutes after
injury. (CNTO5048 versus vehicle: 78.82% ± 0.64 versus 80.16% ± 0.89;
t-test; *P = 0.026; n = 5/group).
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treatment for rheumatological disease, the present find-
ings are the first to demonstrate its potential efficacy for
improving recovery after ICH.
While the blood-brain barrier (BBB) remains imperme-
able to large molecules for the first 12 hours after ICH
[21], permeability increases over the first 24 hours allowing
central nervous system (CNS) exposure to previously ex-
cluded substances, such as blood-borne cytokines includ-
ing TNF-α. Systemic and in situ cytokines contribute to
cerebral edema evolution [22], which then influences func-
tional outcome [19,23,24]. However, the exact mechanism
of edema formation and its contribution to ICH-induced
neurological deficits needs further investigation [25].
Direct injury to CNS cellular components results in
the release of cytokines from immunomodulatory cells
such as microglia, ultimately enhancing edema formation
[26-29]. TNF-α is singularly important. It is one of the
first inflammatory cytokines to be expressed after injury.
TNF-α directly upregulates p-selectin on endovascular
cells, which then interact with integrins leading to
leukocyte infiltration. Preclinical studies [30-32] and
human investigations [33,34] have linked increased
cytokine concentrations with cerebral edema progression
and outcome after ICH.
Though its exact role remains undefined, TNF-α does
not serve as a simple ‘biomarker’ of inflammation, but
rather plays a central role in mediating and extending
neuronal injury after insult [35]. In preclinical models, brain
TNF-α expression is upregulated after ICH. Knockout
of TNF-α or inhibition of TNF-α by a TNF-α-specific
antisense oligodeoxynucleotide is neuroprotective against
ICH [17,36]. In CNS microvascular endothelial cells,
TNF-α can act through NF-κB signaling to repress
claudin-5 promoter activity and therefore downregulate
claudin-5 expression. Since claudin-5 expression is import-
ant for tight junctions, downregulation may be a potential
molecular mechanism of BBB disruption in inflammatory
CNS conditions [37]. Lastly, preclinical data suggest that
modification of TNF-α expression [10,19], and infliximab
in particular [38], attenuates the immune response after
ICH, resulting in neuroprotection.
For these reasons, CNTO5048, a murine infliximab
analog, was tested for its initial potential for translation
as a therapeutic to improve recovery after ICH. Infliximab
is currently FDA-approved for treating chronic inflamma-
tory states such as rheumatoid arthritis. In addition,
infliximab has demonstrated effects in both hippocampal
cell culture [39], and in peripheral nerve injury models
where it reduces brain-derived neurotrophic factor [40].
While data for its use in acute CNS injury are limited,
especially in ICH, TNF-α antagonism as a therapeutic
strategy has gained attention in models of other forms
of injury such as ischemic stroke [41,42], traumatic brain
injury [43,44], and spinal cord injury [45].
While these data are encouraging, several issues should
be addressed before translation to human disease. First,
pre-injury RR latency differences are a possible confounding
variable. Baseline latency differences might suggest fun-
damental group differences despite identical genetic
background, animal age, testing methods, etcetera. Further,
the obvious question is whether CNTO5048 can cross the
BBB after injury. As systemic inflammation is known to
affect brain inflammation [46], it is possible that the
present results are due to systemic TNF-α antagonism;
however, reduction in brain cleaved caspase-3 lends
evidence to the effects of CNTO5048 in the brain. This
is further supported by a lack of effect on brain TNF-α
expression, as transcription should not be affected by
receptor antagonism. Future studies should assess add-
itional downstream products of the TNF-α receptor in the
brain. It would also be of great interest to determine
which cell types (that is, glial versus neuronal) might be
preferentially bound by the drug, and if the effects of
CNTO5048 are brain region-specific (that is, hippocampal
versus cortical).
While the present study rigorously adhered to stroke
therapy academic industry roundtable criteria [47], future
experiments should assess other variables as outlined
in the drug development guidelines from the National
Institute for Neurological Disorders and Stroke [48],
specifically demonstration of the optimal dose and
therapeutic window. Further, long-term outcomes were not
assessed in these experiments, and future experiments
with CNTO5048 should include neurobehavioral assess-
ment at one month or more after injury. In addition, while























Figure 5 Rotorod latencies after intracerebral hemorrhage. Over
the first 7 days after intrastriatal collagenase injection, rotorod
latencies were longer in mice given 7 mg/kg CNTO5048 compared
to those treated with an equivalent volume of phosphate-buffered
saline via tail vein injection at 30 minutes after injury. Due to
differences in pre-injury latencies, post-injury latencies are reported
as percentages of the baseline. Shams are not shown as they
behave like uninjured animals, as previously demonstrated. (ANOVA;
*P = 0.0243; n = 14/group; error bars represent standard deviation).
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CNTO5048 was tolerated in this study, the most obvious
concern would be an increase in infections that might be
associated with cytokine antagonism. True dose-response,
therapeutic window, and toxicity studies would discern
whether this risk is theoretical or concerning, and would
also define important parameters for administration.
Future studies should also include female and aged
animals, and extrapolation of these findings to higher
order animals.
Bearing this in mind, a number of factors are encouraging
for rapid translation of infliximab to treat ICH. First, the
drug is currently FDA-approved for treatment of inflamma-
tory states. It is easily administered, and human toxicity, as
well as drug tolerance, data are available from years of
use since its approval. ICH is a disease without proven
therapy, and murine models of ICH are high throughput.
Further, monoclonal antibodies against TNF-α make sense
as a therapeutic strategy in ICH due to the marked
neuroinflammatory effects seen in the disease. Thus, in
light of the present findings, future study of CNTO5048
might easily address some of these outstanding issues, so
that infliximab will readily progress into early-phase human
clinical trial in ICH.
Conclusions
Post-injury administration of the TNF-α monoclonal anti-
body CNTO5048 improved recovery of vestibulomotor
function in a murine model of ICH that was associated with
reduced neuroinflammation demonstrated by decreased
cerebral edema and cleaved caspase-3. While encouraging
for potential translation of this therapeutic strategy, future
research should explore the potential mechanism, deter-
mine the optimal dose and timing of administration, and
assess efficacy in female, aged, and higher order animals.
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